Tokyo (Japan), August 1, 2017 -LTL Pharma Co., Ltd. (Representative Director, Chairman: Sansei Oka, Representative Director, President: Jiro Mizukawa, 'LTL Pharma') and Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka) announced that from October 1, 2017, LTL Pharma will succeed the marketing approval in Japan from Astellas, for 'Nivadil tablets 2mg, 4mg' (hypertension treatment), 'Solantal tablets 50mg, 100mg' (analgesia/anti-inflammatory), and 'Lowgan tablets 10mg' (hemodynamic improving type antihypertensive) (the 'Products') and Astellas will transfer the distribution rights of the Products in Japan to LTL Pharma.

On March 28, 2017, Astellas and LTL Pharma entered into an Asset Purchase Agreement, under which Astellas will transfer to LTL Pharma its marketing authorization of the Astellas' 16 long-listed products in Japan, supply business of active pharmaceutical ingredients/bulk of the Products to third parties in and outside of Japan and royalty business of the products.

From October 2017, LTL Pharma will provide and collect information as the manufacturer and distributor in Japan and will ensure a stable supply of this product.

Astellas Pharma Inc. published this content on 01 August 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 01 August 2017 02:05:04 UTC.

Original documenthttps://www.astellas.com/en/corporate/news/detail/ltl-pharma-succeeds-marketing-.html

Public permalinkhttp://www.publicnow.com/view/18375E1DEA7D40E036F309E4F7BC4A6BD0D11253